HEART FAILURE AND PHARMACOGENETICS
Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure
Dennis M. McNamara, MD*,*,
Richard Holubkov, PhD ,
Lisa Postava, MBA*,
Karen Janosko, MSN*,
Guy A. MacGowan, MD*,
Michael Mathier, MD*,
Srinivas Murali, MD*,
Arthur M. Feldman, MD, PhD and
Barry London, MD, PhD*
* Cardiovascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Department of Family and Preventive Medicine, School of Medicine, University of Utah, Salt Lake City, Utah
Department of Medicine, Thomas Jefferson Medical Center, Philadelphia, Pennsylvania
Manuscript received November 22, 2003;
revised manuscript received August 13, 2004,
accepted August 17, 2004.
* Reprint requests and correspondence: Dr. Dennis M. McNamara, Director, Heart Failure/Transplantation Program, Cardiovascular Institute, University of Pittsburgh Medical Center, 558 Scaife Hall, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213 (Email: mcnamaradm{at}upmc.edu).
OBJECTIVES: We evaluated the interaction of angiotensin-converting enzyme (ACE) inhibitor therapy with the effect of the ACE D/I polymorphism on heart failure survival.
BACKGROUND: The ACE deletion allele, ACE-D, is associated with increased ACE activity. The utilization of ACE genotyping to predict the impact of ACE inhibitor dose has not been previously evaluated.
METHODS: We prospectively studied 479 subjects with systolic dysfunction (left ventricular ejection fraction 0.25 ± 0.08). Subjects were divided on the basis of ACE inhibitor therapy into low dose ( 50% of target dose, n = 227), standard (high) dose (>50%, n = 201), or those receiving angiotensin receptor antagonists (n = 51). Patients were genotyped for the ACE D/I polymorphism, followed to the end point of death or cardiac transplantation, and transplant-free survival compared by genotype.
RESULTS: The ACE-D allele was associated with an increased risk of events (p = 0.026). In analysis by ACE inhibitor dose, this effect was primarily in the low-dose group (1-year percent event-free survival: II/ID/DD = 86/77/71,2-year = 79/66/59, p = 0.032). In the standard-dose group, the impact was markedly diminished (1-year: II/ID/DD = 91/81/80, 2-year: 77/70/71, p = 0.64). The impact of beta-blockers and high dose ACE inhibitors was greatest in subjects with the ACE DD genotype (p = 0.001) and was less apparent with the II and ID genotypes (p = 0.38).
CONCLUSIONS: Higher doses of ACE inhibitors diminished the impact of the ACE-D allele, and the benefits of beta-blockers and high-dose ACE inhibitors appeared maximal for DD patients. Determination of ACE genotype may help target therapy for patients with heart failure.
|
Abbreviations and Acronyms
| | ACE = angiotensin-converting enzyme | | ARB = angiotensin receptor blocker | | CI = confidence interval | | LVEF = left ventricular ejection fraction | | NYHA = New York Heart Association |
|
This article has been cited by other articles:
|
|
|
|
 
S. R. Auerbach, C. Manlhiot, S. Reddy, C. Kinnear, M. E. Richmond, D. Gruber, B. W. McCrindle, L. Deng, J. M. Chen, L. J. Addonizio, et al.
Recipient Genotype Is a Predictor of Allograft Cytokine Expression and Outcomes After Pediatric Cardiac Transplantation
J. Am. Coll. Cardiol.,
May 19, 2009;
53(20):
1909 - 1917.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Mann and D. M. McNamara
Pharmacogenomics and the Failing Heart: Are We Waiting for Godot?
J. Am. Coll. Cardiol.,
August 19, 2008;
52(8):
652 - 654.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. de Denus, M. Zakrzewski-Jakubiak, M.-P. Dube, F. Belanger, S. Lepage, M.-H. Leblanc, D. Gossard, A. Ducharme, N. Racine, L. Whittom, et al.
Effects of AGTR1 A1166C Gene Polymorphism in Patients with Heart Failure Treated with Candesartan
Ann. Pharmacother.,
July 1, 2008;
42(7):
925 - 932.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ashrafian and H. Watkins
Reviews of Translational Medicine and Genomics in Cardiovascular Disease: New Disease Taxonomy and Therapeutic Implications: Cardiomyopathies: Therapeutics Based on Molecular Phenotype
J. Am. Coll. Cardiol.,
March 27, 2007;
49(12):
1251 - 1264.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. P. Donahue, D. A. Marchuk, and H. A. Rockman
Redefining Heart Failure: The Utility of Genomics
J. Am. Coll. Cardiol.,
October 3, 2006;
48(7):
1289 - 1298.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. McNamara, S. W. Tam, M. L. Sabolinski, P. Tobelmann, K. Janosko, A. L. Taylor, J. N. Cohn, A. M. Feldman, and M. Worcel
Aldosterone Synthase Promoter Polymorphism Predicts Outcome in African Americans With Heart Failure: Results From the A-HeFT Trial
J. Am. Coll. Cardiol.,
September 19, 2006;
48(6):
1277 - 1282.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. S. Ginsburg, M. P. Donahue, and L. K. Newby
Prospects for Personalized Cardiovascular Medicine: The Impact of Genomics
J. Am. Coll. Cardiol.,
November 1, 2005;
46(9):
1615 - 1627.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Koch, W. Latz, M. Eichinger, C. Ganser, A. Schomig, and A. Kastrati
Genotyping of the Angiotensin I-Converting Enzyme Gene Insertion/Deletion Polymorphism by the TaqMan Method
Clin. Chem.,
August 1, 2005;
51(8):
1547 - 1549.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. McDonald
Current guidelines in the management of chronic heart failure: Practical issues in their application to the community population
Eur J Heart Fail,
March 16, 2005;
7(3):
317 - 321.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, O. Ben-Yehuda, D. Berman, G. K. Feld, B. H. Greenberg, J. D. Knoke, K. U. Knowlton, W. Y.W. Lew, J. Narula, D. Sahn, et al.
Highlights of the year in JACC 2004
J. Am. Coll. Cardiol.,
January 4, 2005;
45(1):
137 - 153.
[Full Text]
[PDF]
|
|
|
|
